This study supports the hypothesis that GLP-1 receptor agonists may reduce the symptom burden in fibromyalgia patients, particularly with regard to opioid dependency, fatigue and pain, wrote Nouran Eshak, MB, ChB, rheumatology fellow at Mayo Clinic and the lead investigator of the study
Wegovy (semaglutide 2.4 mg) is a once-weekly injection licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
Quick Answer GLP-1 injections are prescription medications that mimic or activate hormone pathways involved in appetite, fullness, digestion, and blood sugar regulation
It is only approved for adults who fit within those qualifications and for children aged 12 and older who are being treated for chronic weight management
Patients are responsible for confirming eligibility with their HSA/FSA provider
[4] [5] Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain, particularly during the initial titration phase
